

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7645783

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KAI MA	10/21/2021
MELIK ZIYA TÜRKER	10/20/2021
FEI WU	10/20/2021
FENG CHEN	10/20/2021
THOMAS COURTNEY GARDINIER II	10/21/2021
ARANAPAKAM M. VENKATESAN	10/20/2021
GENO J. GERMANO JR.	10/21/2021
RECEIVING PARTY DATA	
Name:	ELUCIDA ONCOLOGY, INC.
Street Address:	1 DEER PARK DRIVE, SUITE E
City:	MONMOUTH JUNCTION
State/Country:	NEW YORK
Postal Code:	08852
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17867025
CORRESPONDENCE DATA	
Fax Number:	(617)371-1037
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-371-1019
Email:	catherine.heath@hoganlovells.com
Correspondent Name:	ROBERT H. UNDERWOOD
Address Line 1:	HOGAN LOVELLS US LLP
Address Line 2:	125 HIGH STREET, SUITE 2010
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	761825.291000
NAME OF SUBMITTER:	ROBERT H. UNDERWOOD
SIGNATURE:	/Robert H. Underwood/
DATE SIGNED:	11/15/2022

Total Attachments: 9

source=2021.10.25__As Filed Assignment (761583.290012)#page1.tif
source=2021.10.25__As Filed Assignment (761583.290012)#page2.tif
source=2021.10.25__As Filed Assignment (761583.290012)#page3.tif
source=2021.10.25__As Filed Assignment (761583.290012)#page4.tif
source=2021.10.25__As Filed Assignment (761583.290012)#page5.tif
source=2021.10.25__As Filed Assignment (761583.290012)#page6.tif
source=2021.10.25__As Filed Assignment (761583.290012)#page7.tif
source=2021.10.25__As Filed Assignment (761583.290012)#page8.tif
source=2021.10.25__As Filed Assignment (761583.290012)#page9.tif

ASSIGNMENT

WHEREAS we, **Kai MA, Melik Ziya TÜRKER, Fei WU, Feng CHEN, Thomas Courtney GARDINIER II, Aranapakam M. VENKATESAN, and Geno J. GERMANO, Jr.**, (each individually an Assignor and collectively Assignors) have made a certain new and useful invention as set forth in an application for Letters Patent of the United States, entitled **METHODS OF FUNCTIONALIZING NANOPARTICLES** and filed concurrently herewith; OR for which an application for Letters Patent of the United States was filed on October 12, 2021 and assigned U.S. Patent Application No. 63/254,837.

AND WHEREAS, **Elucida Oncology, Inc.** (Assignee), a corporation organized under the laws of Delaware and having an ordinary place of business at 1 Deer Park Drive, Suite E, Monmouth Junction, NJ 08852, is desirous of acquiring the entire right, title and interest in and to said invention and in and to any and all Letters Patent of the United States and foreign countries which may be obtained therefor;

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, we do hereby sell, assign, transfer and set over unto Assignee, its legal representatives, successors, and assigns, the entire right, title and interest in and to said invention and the above-mentioned application for Letters Patent, including any utility applications, continuations, continuations-in-part, and divisions of said application, and in and to any and all Letters Patents of the United States and all foreign countries which may be granted therefore and thereon, and all reissues, re-examinations and extensions thereof, and all rights under any and all international agreements, treaties and laws relating to the protection of industrial property including the right of priority, and the right to apply for and obtain in all countries any and all Letters Patents, and the right to procure the grant of all such Letters Patents to Assignee in its own name, the same to be held and enjoyed by Assignee for its own use and benefit and the use and benefit of its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted and/or extended as fully and entirely as the same would have been held by Assignors had this assignment and sale not been made.

AND UPON SAID CONSIDERATIONS, we hereby agree with the said Assignee that we will not execute any writing or do any act whatsoever conflicting with this grant, and that we will, at any time upon request, without further or additional consideration but at the expense of said Assignee, execute such additional assignments and other writings and do such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining utility applications, divisions, continuations, continuations-in-part, reexamined, reissued, or extended Letters Patent of the United States and any and all foreign countries on said invention, and in enforcing any rights or chose in action accruing as a result of such applications or patents, by giving testimony in any proceedings or transactions involving such applications or patents, and by executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of the successors, assigns and legal representatives of Assignors and Assignee;

AND we hereby grant Assignee, its legal representatives, successors and assigns, the power to insert on this instrument any further identification that may be necessary or desirable to comply with the recordation rules of any appropriate and competent authority, including, without limitation, the United States Patent and Trademark Office.

AND we hereby agree that this Assignment may be executed in two or more counterparts each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

AND we request the Commissioner for Patents and Trademarks to issue any Letters Patent of the United States which may be issued for said invention and on said application to Assignee, its legal representatives, successors or assigns, as the sole owner of the entire right, title and interest in and to said patent and the invention covered thereby.

[signature page follows]

IN TESTIMONY WHEREOF, I have hereunto set my hands.

ASSIGNOR

Kai Ma

Signature

Kai MA

Print Name

10/21/2021

Execution Date

Witness 1

Signature

Print Name

Witness 2

Signature

Print Name

IN TESTIMONY WHEREOF, I have hereunto set my hands.

ASSIGNOR

Melik Ziya Türker
Signature

Melik Ziya TÜRKER
Print Name

10/20/2021
Execution Date

Witness 1

Signature

Print Name

Witness 2

Signature

Print Name

IN TESTIMONY WHEREOF, I have hereunto set my hands.

ASSIGNOR

Fei Wu
Signature

Fei WU
Print Name

10/20/2021
Execution Date

Witness 1

Signature

Print Name

Witness 2

Signature

Print Name

IN TESTIMONY WHEREOF, I have hereunto set my hands.

ASSIGNOR

Feng Chen

Signature

Feng CHEN

Print Name

2021-10-20

Execution Date

Witness 1

Signature

Print Name


Witness 2

Signature

Print Name

IN TESTIMONY WHEREOF, I have hereunto set my hands.

ASSIGNOR


Signature

Thomas Courtney GARDINIER II

Print Name

21 OCT 2021
Execution Date

Witness 1

Signature

Print Name


Witness 2

Signature

Print Name

IN TESTIMONY WHEREOF, I have hereunto set my hands.

ASSIGNOR


Signature

Aranapakam M. VENKATESAN

Print Name

Oct 20th 2021
Execution Date

Witness 1

Signature

Print Name

Witness 2

Signature

Print Name

IN TESTIMONY WHEREOF, I have hereunto set my hands.
ASSIGNOR

Geno J. Germano, Jr.
Signature

Geno J. GERMANO, Jr.

Print Name

October 21, 2021
Execution Date

Witness 1

Signature

Print Name

Witness 2

Signature

Print Name

Acknowledged and Accepted by:

Elucida Oncology, Inc.

Geno J. Germano, Jr.

Print Name: Geno J. GERMANO, Jr.

Print Title: President and CEO

Date: OCTOBER 21, 2021